The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Crossref DOI link: https://doi.org/10.1007/s00415-017-8594-9
Published Online: 2017-09-06
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pardo, Gabriel http://orcid.org/0000-0002-2207-3708
Jones, David E. http://orcid.org/0000-0001-9043-2621
Funding for this research was provided by:
Biogen
License valid from 2017-09-06